Search Results for: "Other News to Note"
-
Other News To Note
Repligen plans to file a marketing authorization application in the European Union for SecreFlo during the first quarter. (See BioWorld Today, March 27, 2008BioWorld Today | Wednesday, February 22, 2012 -
Other News To Note
If the European Commission adopts the CHMP's recommendation, Pixuvri would be approved for marketing in the 27 member countries of the European Union, as well as the European Economic AreaBioWorld Today | Tuesday, February 21, 2012 -
Other News To Note
Alexza is working with partner Grupo Ferrer International Inc., of Barcelona, Spain, to develop Adasuve in the European Union and other territoriesBioWorld Today | Tuesday, February 14, 2012 -
Other News To Note
Intercell AG, of Vienna, Austria, said it completed a pivotal Phase III study of its Japanese encephalitis vaccine, Ixiaro/Jespect, in 1,869 children in the Philippines and a second Phase III study in the European Union, U.SBioWorld International | Wednesday, February 8, 2012 -
Other News To Note
Navidea Biopharmaceuticals Inc. (formerly Neoprobe Corp.), of Dublin, Ohio, plans to file a marketing authorization application in the European Union by year-end for the radiopharmaceutical Lymphoseek (99mTc tilmanocept for injectionBioWorld Today | Friday, February 3, 2012 -
Other News To Note
Telormedix SA, of Bioggio, Switzerland, said it was elected as a member of a collaborative research program dubbed TIMER (targeting novel mechanisms of resolution in inflammation), which is funded with €3 million (US$3.9 million) from the European Union to establish a robust collaboration comprising a team of European universities and research institutionsBioWorld Today | Wednesday, February 1, 2012 -
Other News To Note
Amarin plans to use proceeds to fund the commercial launch of triglyceride-lowering compound AMR101 (ethyl icosapentate) and the patient enrollment in a cardiovascular outcomes study of the compound...Vibativ was approved in Europe last year for the treatment of adults with nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives aren't suitableBioWorld International | Wednesday, January 11, 2012 -
Other News To Note
That designation would provide 10 years of marketing exclusivity in the European Union upon approvalBioWorld Today | Wednesday, January 4, 2012 -
Other News To Note
Enkam Pharmaceuticals A/S, of Copenhagen, Denmark, said the European Union awarded a €6 million grant (US$7.84 million) to a consortium led by Enkam to fund clinical studies of the company's lead product in treating Alzheimer's diseaseBioWorld International | Wednesday, December 28, 2011 -
Other News To Note
Final approval, which would allow products manufactured at the facility to be distributed in the European Union, is expected in the first quarter of 2012BioWorld Today | Tuesday, December 20, 2011 -
Other News To Note
Alexion Pharmaceuticals Inc., of Cheshire, Conn., said the European Commission extended the therapeutic indication for Soliris (eculizumab) in the European Union to include pediatric and adult patients with atypical hemolytic uremic syndrome (aHUSBioWorld Today | Wednesday, November 30, 2011 -
Other News To Note
ViroPharma anticipates launching Plenadren in the European Union in about one year. (See BioWorld Today, Oct. 28, 2011BioWorld Today | Wednesday, November 16, 2011 -
Other News To Note
That designation confers clinical and regulatory incentives and would guarantee 10 years of marketing exclusivity in the European Union upon approvalBioWorld International | Wednesday, November 9, 2011 -
Other News To Note
That designation confers clinical and regulatory incentives and would guarantee 10 years of marketing exclusivity in the European Union upon approvalBioWorld Today | Thursday, November 3, 2011 -
Other News To Note
Celldex Therapeutics Inc., of Needham, Mass., said the European Medicines Agency granted orphan drug designation in the European Union for rindopepimut (CDX-110) for the treatment of glioblastomaBioWorld Today | Tuesday, November 1, 2011 -
Other News To Note
and orphan medicinal product designation from the European Medicines Authority in the European Union for follicular lymphoma and mantle cell lymphomaBioWorld Today | Friday, October 28, 2011 -
Other News To Note
Xigris, approved by the FDA in November 2001 and licensed in the European Union in 2002, remains the only product approved specifically for patients at high risk of death from severe sepsis and joins a long list of failed sepsis drugsBioWorld Today | Wednesday, October 26, 2011 -
Other News To Note
The five-year, $54.5 million European research initiative was launched Oct. 1 with funding from the European Union and collaborating organizationsBioWorld Today | Tuesday, October 18, 2011 -
Other News To Note
Ligand Pharmaceuticals Inc., of La Jolla, Calif., said it signed a global licensing deal with Chiva Pharmaceuticals Inc., of Los Altos Hills, Calif., for Fablyn (lasofoxifene), a selective estrogen receptor modulator, approved in the European Union in 2009 to treat osteoporosis in postmenopausal women at increased risk of fractureBioWorld Today | Tuesday, October 11, 2011 -
Other News To Note
The partnership will receive funding from the European Union as part of the Eurostars program aimed at supporting innovation within the EUBioWorld International | Wednesday, August 3, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.